CoreQuest's strategy is to implement a cost-effective architecture, minimising infrastructure and overhead costs while maximising access to world-class expertise.
Thanks to the substantial skills and experience in the international pharmaceutical industry, CoreQuest's management closely controls these outsourcing activities.
Our most advanced pharmaceutical program regards the treatment of end stage renal disease (ESRD), a debilitating disease that carries significant implications for health care practitioners and their patients.
Indeed, we are developing a new set of hypertonic solutions for peritoneal dialysis (PD), a renal replacement therapy whereby toxin and water removal occur through the patient's peritoneal membrane, a large membrane surrounding the organs below the diaphragm.
To complement our PD program and in collaboration with Prof.Dr. Diego Barrettino and his research team at the University of Applied Sciences of Southern Switzerland (SUPSI), we are developing an innovative wireless multi-frequency segmental bioimpedance device that will help to monitor lung edema and fluid overload.
The developed medical system will be part of an innovative home-based therapy monitoring system that will drastically improve the quality of life of dialysis patients affected by renal impairment or end stage renal disease.
Diabetes mellitus is the leading cause of ESRD, approximately 35% of newly diagnosed cases, followed closely by hypertension, approximately 30%.
Other causes of ESRD include primary and secondary glomerulapathies, cystic and interstitial renal diseases, and obstructive uropathy. ESRD is irreversible and lethal if untreated. Life expectancy for adults individuals affected by ESRD is still less than a decade, making this disease similar to other serious chronic illness such as cancer.
QESRD represents a public health burden that could become unsustainable in about a decade. It has been estimated that people suffering from CRF worldwide are 500 million, of whom more than 2 million are under dialysis treatment.
Our new hypertonic solutions for PD therapy contain low amounts of glucose in association with naturally occurring osmotic agents. The osmolar property of the solution, and hence the ability to achieve a satisfactory filtration process across the peritoneum, is ensured by the presence of new osmolar agents that possess an excellent biocompatibility profile and are capable to exert a significant systemic action in mitigating conditions such as insulin resistance.
IWe have conducted a number of in vitro and in vivo studies, which have shown that our hypertonic solutions are more biocompatible than those based on glucose only. Our most advanced hypertonic solutions are in a clinical development and we have completed the phase II clinical trials. The results of our clinical trials have been published in major nephrology journals (see news).
Another program regards the development of our hypertonic solutions to reduce adhesions following abdominal surgery, one of the greatest unresolved medical problems in medicine today. Indeed, recent epidemiological data have demonstrated that, despite advances in surgical techniques in recent years, the burden of adhesion-related complications has not changed.
The mode of action of our anti-adherence hypertonic solutions provides a temporary separation of peritoneal surfaces by hydroflotation. This significantly reduces tissue contact during the critical period of fibrin formation and mesothelial regeneration following surgery, thereby providing a barrier to adhesion formation.